Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,058.62
    +2,772.84 (+3.25%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Ultimovacs ASA: New share capital registered

Ultimovacs ASA
·1 min read
Ultimovacs ASA
Ultimovacs ASA

Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive program.

The share capital increase related to the share issue of 130,700 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,439,646.10, divided into 34,396,461 shares, each with a par value of NOK 0.10.

For further information, please contact:

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355

ADVERTISEMENT

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
        
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632